Heidelberg, Germany

Reinhard Wallich

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 47(Granted Patents)


Company Filing History:


Years Active: 1999-2004

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Reinhard Wallich: Innovator in Lyme Disease Treatment

Introduction

Reinhard Wallich is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Lyme disease. With a total of four patents to his name, Wallich's work has the potential to impact the medical community significantly.

Latest Patents

Wallich's latest patents include a medicament for treating manifested Lyme disease. This pharmaceutical composition contains an antibody as an active agent that is specific for the 24 kDa antigen (OspC) of Borrelia burgdorferi. Another significant patent involves novel Borrelia and OspA antigens derived from them. These antigens exhibit little homology with known OspA's, making them useful as vaccines and diagnostic reagents. Additionally, he has disclosed multicomponent vaccines based on OspA's from different Borrelia groups.

Career Highlights

Throughout his career, Reinhard Wallich has worked with prominent organizations such as the Max Planck Society for the Advancement of Science and SmithKline Beecham Biologicals. His experience in these institutions has allowed him to develop innovative solutions in the field of biotechnology.

Collaborations

Wallich has collaborated with notable colleagues, including Markus M. Simon and Michael D. Kramer. These partnerships have contributed to the advancement of his research and the development of his patents.

Conclusion

Reinhard Wallich's contributions to the treatment of Lyme disease through his innovative patents highlight his role as a significant figure in the pharmaceutical industry. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…